OKYO Pharma Limited’s SEC filings document foreign-private-issuer reports on Form 6-K for a clinical-stage biopharmaceutical company with ordinary shares listed on Nasdaq. The disclosures cover urcosimod clinical and regulatory updates for neuropathic corneal pain, scientific-meeting materials, and descriptions of the company’s focus on inflammatory eye diseases and other ocular disorders.
The filing record also includes capital-structure and financing disclosures tied to Form F-3 registration statements, ordinary-share offerings, underwriter option exercises, and insider share purchases. These records present formal updates on the company’s securities, ownership activity, incorporated exhibits, and material announcements furnished under Exchange Act Rule 13a-16.
OKYO Pharma Ltd (OKYO) announced that the first patients have been enrolled in its Phase 3 NEPTUNE trial of investigational urcosimod for neuropathic corneal pain. Dr. Melissa Toyos enrolled the first patients at Toyos Clinic in Nashville. Participants will receive 4 drops per day for 12 weeks, and the trial is designed as a registrational study in accordance with FDA guidance.
The study is planned for clinical sites across the United States and Europe, including Italy, Spain and France. Its primary efficacy endpoint is change from baseline to the end of treatment in ocular pain assessed by VAS score; additional endpoints include quality-of-life scores and in-vivo confocal microscopy findings.
OKYO Pharma Ltd (OKYO) announced it will present and participate at ophthalmic conferences. The American Academy of Optometry takes place September 30 to October 1, 2026, in Anaheim, where the company’s leadership team will engage optometric experts; the American Academy of Ophthalmology is scheduled for October 9–12, 2026, in New Orleans, for engagement with ophthalmology experts. At Eyecelerator in New Orleans on October 8, Chief Executive Officer Robert J. Dempsey is scheduled to present “Addressing Unmet Needs in Corneal and Anterior Segment Diseases” at 1:29 p.m. in the Anterior Segment breakout, Room 243–245.
OKYO also said it plans to initiate a global Phase 3 pivotal clinical trial of urcosimod in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen for neuropathic corneal pain. The release describes the company as developing investigational therapies for neuropathic corneal pain and anterior segment eye diseases.
OKYO Pharma Ltd (OKYO), a clinical-stage biopharmaceutical company focused on neuropathic corneal pain and anterior segment eye diseases, reported that it will present at the Ophthalmology Futures European Forum and the 5th Annual ESCRS iNovation Day in London in September 2026. These meetings bring together ophthalmologists, clinical innovators, industry leaders, emerging companies and the financial community. OKYO states that ongoing conference participation supports advancement of urcosimod, its lead asset, through a global Phase 3 pivotal NEPTUNE trial for neuropathic corneal pain. The company notes that its presence at these events follows recent positive feedback from a U.S. FDA Type D meeting validating its regulatory and clinical path for urcosimod and the filing of its Annual Report reflecting a strengthened cash position. OKYO also plans to initiate a global Phase 3 pivotal trial in the second half of the year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain.
OKYO Pharma Ltd (OKYO), a clinical-stage biopharmaceutical company focused on neuropathic corneal pain (NCP) and anterior segment eye diseases, reported that it will participate in a fireside chat at the Cantor Global Healthcare Conference being held September 9-11, 2026.
The session, featuring Chief Medical Officer Flavio Mantelli and Chief Development Officer Gary Jacob, is scheduled for September 10 at 8:35 AM, moderated by Eric Fitzgerald of Cantor Fitzgerald, and the company will also be available for one-on-one meetings. OKYO notes that this appearance follows recent positive feedback from a U.S. FDA Type D meeting that validated its regulatory and clinical path forward for urcosimod, as well as the filing of its Annual Report reflecting a strengthened cash position.
OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for treating NCP.
OKYO Pharma Limited, a Guernsey-based company whose ordinary shares of no par value trade on the Nasdaq Capital Market, has prepared Amendment No. 1 to its annual report for the year ended March 31, 2026.
The amended report only revises the exhibit table to add the company’s Clawback Policy as Exhibit 97, which had been omitted previously. OKYO states that no other disclosures have been modified and that the amendment does not reflect events after the original July 20, 2026 report. As of July 15, 2026, the company had 52,479,527 ordinary shares outstanding.
OKYO Pharma Ltd director John P. Brancaccio reported an open-market purchase of 5,000 shares of common stock on July 21, 2026 at $1.477 per share. Following this trade, he directly owns 35,201 shares.
The amended insider report corrects the transaction code for this purchase and indicates the trade was not made under a Rule 10b5-1 trading plan.
OKYO Pharma Ltd reported that Chief Executive Officer Robert John Dempsey purchased 15,000 shares of common stock on July 22, 2026 at $1.539 per share in a transaction coded as a purchase in an open market or private transaction. Following this trade, he directly holds 15,000 shares. The Form 4/A states it amends the July 23, 2026 filing solely to correct the transaction code, with no other transactions affected and the Rule 10b5-1 trading-plan box left unchecked.
OKYO Pharma Ltd reported an amended insider transaction for Chief Development Officer Gary S Jacob. The amendment only corrects the code for an open market purchase on July 21, 2026, when he bought 3,500 common shares at $1.40, increasing his direct holdings to 112,420 shares.
OKYO Pharma Ltd reported that director and ten percent owner Gabriele M Cerrone, through Panetta Partners Limited, purchased 22,500 shares of common stock on July 21, 2026 in an open-market transaction at $1.45 per share. After this indirect purchase, the associated entity holds 10,873,916 common shares. This amended filing solely corrects the transaction code and reflects a trade not made under a Rule 10b5-1 plan.
OKYO Pharma Ltd director and ten percent owner Gabriele M. Cerrone, through Panetta Partners Limited, purchased 25,000 shares of common stock in an open market transaction on July 20, 2026 at $1.40 per share, increasing his indirect holdings to 10,851,416 shares. This amendment corrects the transaction code for that purchase; no other transactions are changed.